

A three-amino-acid anti-inflammatory peptide

KPV is the smallest compound on the 2026 PCAC docket and one of the more mechanistically tidy ones: it is the active tail of a hormone the body already uses to switch inflammation down.

● In Plain English

Your body makes a hormone called α -MSH that does two unrelated jobs: it darkens skin, and it calms inflammation. KPV is just the tail end of that hormone — the part that appears to carry the calming effect without the pigment effect. Being only three amino acids long makes it unusually small, stable and easy to characterise, which is a genuine advantage over most peptides in this category.

What people use it for. Inflammatory conditions — gut inflammation and skin conditions being the two most common — usually as part of the KLOW blend rather than alone.

What to know before you buy. KPV has one practical advantage over almost everything else in this category: at three amino acids, it is small enough that there is no real ambiguity about what you are getting. The identity problems that plague BPC-157 and TB-500 barely apply here. What it shares with them is the absence of completed human trials — the mechanism is well understood, the clinical proof is not.

● What It's Used For

GOAL	WHAT THAT RESTS ON
Calming inflammation	Derived from α -MSH, a hormone your body already uses to switch inflammation down
Gut inflammation	Reduced inflammatory signalling in intestinal cells and improvement in rodent colitis models
Skin conditions	Wound-healing and dermatological models
Clean identity	At three amino acids, one of the few peptides here with no ambiguity about what is in the vial

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.

● How to Buy It

AVAILABLE IN THESE BLENDS

KLOW 80mg — BPC-157 + TB-500 + KPV + GHK-Cu

\$110

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

This compound is supplied as part of the blends above rather than as a standalone vial. **Ships sealed and lyophilized** — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

● At a Glance

CLASS	Tripeptide (lysine-proline-valine); the C-terminal fragment of α -MSH
MECHANISM	Retains the anti-inflammatory activity of α -MSH without its pigmentary effects; acts on intracellular inflammatory signalling including NF- κ B
PRECLINICAL	Colitis, wound healing and dermatological models, largely rodent and in-vitro
HUMAN DATA	No completed randomised controlled trial
REVIEWED FOR	Wound healing and inflammatory conditions
REGULATORY (US)	Not FDA-approved. PCAC recommended for 503A listing 23 July 2026; no FDA action taken
FORMAT	Sold within the KLOW blend

3

AMINO ACIDS

8-6-1

PCAC VOTE

α -MSH

PARENT HORMONE

0

COMPLETED RCTS

REGULATORY STATUS — READ THIS FIRST

On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted **8-6-1 to recommend** KPV (free base and acetate) for the Section 503A bulk drug substances list. That vote is **advisory only**. As of 4 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA's own scientific reviewers had recommended *against* all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency's decision is weaker here than normal. Several outlets have reported this as the FDA "clearing", "approving" or "adding" these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.

● What the Research Shows

KPV's preclinical literature clusters around inflammatory conditions of the gut and skin. Reported effects include reduced inflammatory signalling in intestinal epithelial cells, improvement in rodent colitis models, and accelerated closure in wound-healing models. Interest in topical and oral routes reflects the molecule's small size and stability.

What is missing is the same thing missing across this docket: controlled human trials. The mechanism is well-characterised and the parent hormone is well understood, but that is mechanistic plausibility, not demonstrated clinical benefit.

One genuine advantage

The identity problem FDA raised for BPC-157 and TB-500 applies far less here. A three-residue peptide has an unambiguous sequence and a straightforward molecular weight, so the vendor-to-vendor variability concern is materially smaller than for the longer, less settled compounds on the same agenda.

THE BOTTOM LINE

A clean mechanism, a well-understood parent hormone, easy characterisation and a plausible anti-inflammatory rationale — paired with no completed human trials. KPV is a reasonable candidate for the mechanism it claims; it is not a demonstrated treatment for anything.

● Also in the Range

Sold within **KLOW**, which pairs it with BPC-157, TB-500 and GHK-Cu. KPV is the only anti-inflammatory component in that blend.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** FDA PCAC meeting materials and briefing documents, 23-24 July 2026; Hyman, Phelps & McNamara FDA Law Blog, 24 and 28 July 2026; Mintz, 29 July 2026; Polsinelli, 22 April 2026.